Experimental pill aims to boost radiation against deadly brain cancer

NCT ID NCT06829173

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental drug called XRD-0394 combined with radiation therapy in 39 people with high-grade glioma, an aggressive brain cancer. The drug is designed to make radiation more effective at killing tumor cells. The main goal is to find a safe dose and check for side effects, while also tracking how long patients live without the cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XRD-0394 (an experimental pill that may make radiation more effective)
What this could lead to: If it works, this could point toward a new way to treat high-grade gliomas by making radiation work better against the tumor.
What could go wrong: This is a very early, small trial (39 people) focused on safety and dosing. It may not show clear benefit, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH GRADE GLIOMA

Contacts and locations

Locations

NYU Langone Health
RECRUITING

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.